Peptide Drug Conjugates Market, By Product (OctreoScan, Lutathera, Pluvicto, Illuccix and Others), By Type, By Disease, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2026-2033
|
Report ID
ANV6186
|
Published Date
October 2026
|
Pages
308
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Peptide Drug Conjugates market size was valued at US$ 5,280.1 Million in 2025, expanding at a CAGR of 11.9% from 2026 to 2033.
Peptide Drug Conjugates (PDCs) are considered one of the forms of targeted therapy that involves conjugation of a pharmacologically active drug with a peptide carrier through a cleavable or non-cleavable linker. The concept of peptide drug conjugate is based on the targeting peptide (ability to interact with a specific receptor located on the surface of the target cell or tissue), the drug molecule that should be delivered and linkers coupling the drug and peptide molecules. The PDCs possess a number of advantages over the ADCs that could be used in oncology and metabolic and rare diseases.
Peptide Drug Conjugates Market- Market Dynamics
Rising Demand for Oncology Therapeutics To Accelerate Market Growth
The rising demand for oncology therapeutics is driving the utilisation of peptide drug conjugates because of their targeted drug delivery, improved specificity, and increased therapeutic efficacy through reduced side effects, improving the quality of healthcare for oncology patients. For example, in January 2026, according to NIH.gov, there were 60 oncology Marketing Authorisation Applications (MAAs) in the EU from January 2020 to January 2025, where 12 are being approved each year, and out of the 59 applications (in the study period), 59 had a positive opinion, in which 28 (47%) are blood cancers, 10 (17%) are lung cancers, and 6 (10%) are breast cancers. The study further reveals that around 50% of applications are biotech products, and 31% are monoclonal antibodies. These trends are expected to support peptide drug conjugate adoption in oncology treatment and development.
Peptide Drug Conjugates Market- Segmentation Analysis:
The Global Peptide Drug Conjugates market is segmented on the basis of Product, Type, Disease, and Region.
Pluvicto holds a significant share in the peptide drug conjugate because of the drug as a means for treating advanced cases of prostate cancer using radioligand therapy. In March 2025, Novartis was the quality FDA approval in the US for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), the treatment of PSMA-positive metastatic prostate cancer, as a first-line treatment prior to chemotherapy. This approval will drive up the drug sales threefold due to the number of eligible patients increasing. This expanded approval is expected to increase Pluvicto adoption and support its manufacturers\' growth.
Peptide Drug Conjugates Market- Geographical Insights
North America holds a notable position in the Peptide Drug Conjugates market because of the increase in the occurrence of cancer and chronic diseases as well as the increased uptake of targeted treatment. For instance, in June 2026, according to the U.S. Centers for Disease Control and Prevention (Gov), the age-adjusted rate of newly diagnosed cancers in the USA was 453.4 cases per 100,000 people. In urban areas, it was 450.9 per 100,000 people, while in rural regions, it was 466.6 cases of cancer per 100,000 people. Among men, it was 490.4 per 100,000 people, while among women, it was 428.9 cases per 100,000 people. This will propel the demand for targeted peptide-based cancer treatment in the region.
Europe’s Peptide Drug Conjugates market will get support due to its high clinical research strength and government policies to encourage innovations in biotechnology. For instance, in September 2026, according to the European Commission’s CORDIS, biotechnology adds up to close to EUR 40 billion each year to the European Union economy, where more than 80% comes from health biotechnology. Furthermore, there has been a double growth rate in the biotechnology industry in Europe in the past ten years compared to the economy overall.
The innovation in the biotechnology sector is being encouraged through Europe with the help of its Horizon Europe initiative, wherein collaboration in research and innovation in health, agriculture, food, energy, industrial production, chemistry, materials, and the environment is being promoted. In addition, the European Commission had put forward the concept of the European Biotech Act in December 2025 to enhance the competitiveness of the biotechnology sector within the region. These initiatives are expected to propel peptide drug conjugate research, development, and commercialization in the region.
Peptide Drug Conjugates Market- Competitive Landscape:
Some of the key participants in the Peptide Drug Conjugates market include Bicycle Therapeutics plc, Oncopeptides AB, Theratechnologies Inc., Cybrexa Therapeutics, and Angiochem Inc. The growth in the market is supported by developments in targeted drug delivery, peptide-linker technology, and increasing use of PDCs for the treatment of various diseases, including oncology. In June 2026, Oncopeptides AB started conducting research using OP-701 (INSULA) on patients with glioblastoma, which was the first time when its patented Peptide Drug Conjugate (PDC) platform was subjected to examination in glioblastoma following its success in multiple myeloma. Therefore, advancement in peptide drug conjugate platforms is contributing towards improvements in targeted therapy and oncology.
Recent Developments:
- In July 2025, Theratechnologies Inc. announced that the company has signed a definitive agreement to be acquired by CB Biotechnology, LLC, a subsidiary of Future Pak, at a consideration of approximately US$254 million, including contingent value rights, to develop further its portfolio of peptide-drug conjugates (PDC) with su-docetaxel zendusortide (TH1902).
- In March 2025, Cybrexa Therapeutics announced new preclinical data for its alphalex™ peptide-drug conjugates with tumor-selective targeting and anticancer activity supporting the further development of its pipeline of peptide-drug conjugates (PDC).
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PEPTIDE DRUG CONJUGATES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Novartis AG
- AstraZeneca PLC
- Oncopeptides AB
- Bicycle Therapeutics plc
- Cybrexa Therapeutics, Inc.
- Angiochem Inc.
- Soricimed Biopharma Inc.
- Theratechnologies Inc.
- PeptiDream Inc.
- Curium US LLC
- ProteinQure Inc.
- Protagonist Therapeutics, Inc.
- PepGen Corporation
- Italfarmaco S.p.A.
- Zealand Pharma A/S
- BioNTech SE
- Others
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033
- OctreoScan
- Lutathera
- Pluvicto
- Illuccix
- Others
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Therapeutic
- Diagnostic
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Multiple Myeloma
- Others
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
TABLE OF CONTENT
1. Peptide Drug Conjugates Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Peptide Drug Conjugates Market Snippet by Product
2.1.2. Peptide Drug Conjugates Market Snippet by Type
2.1.3. Peptide Drug Conjugates Market Snippet by Disease
2.1.4. Peptide Drug Conjugates Market Snippet by Country
2.1.5. Peptide Drug Conjugates Market Snippet by Region
2.2. Competitive Insights
3. Peptide Drug Conjugates Key Market Trends
3.1. Peptide Drug Conjugates Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Peptide Drug Conjugates Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Peptide Drug Conjugates Market Opportunities
3.4. Peptide Drug Conjugates Market Future Trends
4. Peptide Drug Conjugates Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Peptide Drug Conjugates Market : Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Peptide Drug Conjugates Market Landscape
6.1. Peptide Drug Conjugates Market Share Analysis, 2025
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Peptide Drug Conjugates Market – By Product
7.1. Overview
7.1.1. Segment Share Analysis, By Product, 2025 & 2033 (%)
7.1.2. OctreoScan
7.1.3. Lutathera
7.1.4. Pluvicto
7.1.5. Illuccix
7.1.6. Others
8. Peptide Drug Conjugates Market – By Type
8.1. Overview
8.1.1. Segment Share Analysis, By Type, 2025 & 2033 (%)
8.1.2. Therapeutic
8.1.3. Diagnostic
9. Peptide Drug Conjugates Market – By Disease
9.1. Overview
9.1.1. Segment Share Analysis, By Disease, 2025 & 2033 (%)
9.1.2. Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
9.1.3. Multiple Myeloma
9.1.4. Others
10. Peptide Drug Conjugates Market – By Geography
10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
10.2. North America
10.2.1. Overview
10.2.2. Peptide Drug Conjugates Key Manufacturers in North America
10.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.2.4. North America Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.2.5. North America Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.2.6. North America Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.2.7. U.S.
10.2.7.1. Overview
10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.7.3. U.S. Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.2.7.4. U.S. Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.2.7.5. U.S. Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.2.8. Canada
10.2.8.1. Overview
10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.2.8.3. Canada Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.2.8.4. Canada Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.2.8.5. Canada Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3. Europe
10.3.1. Overview
10.3.2. Peptide Drug Conjugates Key Manufacturers in Europe
10.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.3.4. Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.5. Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.6. Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.7. Germany
10.3.7.1. Overview
10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.7.3. Germany Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.7.4. Germany Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.7.5. Germany Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.8. UK
10.3.8.1. Overview
10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.8.3. UK Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.8.4. UK Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.8.5. UK Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.9. France
10.3.9.1. Overview
10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.9.3. France Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.9.4. France Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.9.5. France Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.10. Italy
10.3.10.1. Overview
10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.10.3. Italy Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.10.4. Italy Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.10.5. Italy Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.11. Spain
10.3.11.1. Overview
10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.11.3. Spain Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.11.4. Spain Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.11.5. Spain Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.12. The Netherlands
10.3.12.1. Overview
10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.12.3. The Netherlands Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.12.4. The Netherlands Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.12.5. The Netherlands Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.13. Sweden
10.3.13.1. Overview
10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.13.3. Sweden Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.13.4. Sweden Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.13.5. Sweden Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.14. Russia
10.3.14.1. Overview
10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.14.3. Russia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.14.4. Russia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.14.5. Russia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.15. Poland
10.3.15.1. Overview
10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.15.3. Poland Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.15.4. Poland Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.15.5. Poland Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.16. Denmark
10.3.16.1. Overview
10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.16.3. Denmark Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.16.4. Denmark Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.16.5. Denmark Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.3.17. Rest of Europe
10.3.17.1. Overview
10.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.3.17.3. Rest of the Europe Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.3.17.5. Rest of the Europe Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4. Asia Pacific (APAC)
10.4.1. Overview
10.4.2. Peptide Drug Conjugates Key Manufacturers in Asia Pacific
10.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.4.4. APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.5. APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.6. APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.7. China
10.4.7.1. Overview
10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.7.3. China Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.7.4. China Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.7.5. China Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.8. India
10.4.8.1. Overview
10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.8.3. India Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.8.4. India Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.8.5. India Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.9. Japan
10.4.9.1. Overview
10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.9.3. Japan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.9.4. Japan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.9.5. Japan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.10. South Korea
10.4.10.1. Overview
10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.10.3. South Korea Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.10.4. South Korea Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.10.5. South Korea Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.11. Australia
10.4.11.1. Overview
10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.11.3. Australia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.11.4. Australia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.11.5. Australia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.12. Indonesia
10.4.12.1. Overview
10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.12.3. Indonesia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.12.4. Indonesia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.12.5. Indonesia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.13. Thailand
10.4.13.1. Overview
10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.13.3. Thailand Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.13.4. Thailand Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.13.5. Thailand Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.14. Philippines
10.4.14.1. Overview
10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.14.3. Philippines Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.14.4. Philippines Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.14.5. Philippines Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.15. Taiwan
10.4.15.1. Overview
10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.15.3. Taiwan Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.15.4. Taiwan Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.15.5. Taiwan Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.16. Vietnam
10.4.16.1. Overview
10.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.16.3. Vietnam Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.16.4. Vietnam Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.16.5. Vietnam Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.4.17. Rest of APAC
10.4.17.1. Overview
10.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.4.17.3. Rest of APAC Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.4.17.5. Rest of APAC Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.5. Latin America (LATAM)
10.5.1. Overview
10.5.2. Peptide Drug Conjugates Key Manufacturers in Latin America
10.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.5.4. LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.5.5. LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.5.6. LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.5.7. Brazil
10.5.7.1. Overview
10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.7.3. Brazil Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.5.7.4. Brazil Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.5.7.5. Brazil Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.5.8. Mexico
10.5.8.1. Overview
10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.8.3. Mexico Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.5.8.4. Mexico Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.5.8.5. Mexico Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.5.9. Argentina
10.5.9.1. Overview
10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.9.3. Argentina Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.5.9.4. Argentina Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.5.9.5. Argentina Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.5.10. Colombia
10.5.10.1. Overview
10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.10.3. Colombia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.5.10.4. Colombia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.5.10.5. Colombia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.5.11. Rest of LATAM
10.5.11.1. Overview
10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.5.11.3. Rest of LATAM Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.5.11.4. Rest of LATAM Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.5.11.5. Rest of LATAM Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6. Middle East and Africa (MEA)
10.6.1. Overview
10.6.2. Peptide Drug Conjugates Key Manufacturers in Middle East and Africa
10.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
10.6.4. MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.5. MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.6. MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6.7. Saudi Arabia
10.6.7.1. Overview
10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.7.3. Saudi Arabia Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.7.4. Saudi Arabia Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.7.5. Saudi Arabia Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6.8. UAE
10.6.8.1. Overview
10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.8.3. UAE Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.8.4. UAE Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.8.5. UAE Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6.9. Israel
10.6.9.1. Overview
10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.9.3. Israel Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.9.4. Israel Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.9.5. Israel Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6.10. Turkey
10.6.10.1. Overview
10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.10.3. Turkey Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.10.4. Turkey Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.10.5. Turkey Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6.11. Algeria
10.6.11.1. Overview
10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.11.3. Algeria Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.11.4. Algeria Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.11.5. Algeria Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6.12. Egypt
10.6.12.1. Overview
10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.12.3. Egypt Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.12.4. Egypt Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.12.5. Egypt Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6.13. Iran
10.6.13.1. Overview
10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.13.3. Iran Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.13.4. Iran Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.13.5. Iran Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6.14. Qatar
10.6.14.1. Overview
10.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.14.3. Qatar Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.14.4. Qatar Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.14.5. Qatar Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
10.6.15. Rest of MEA
10.6.15.1. Overview
10.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
10.6.15.3. Rest of MEA Market Size and Forecast, By Product, 2020 - 2033 (US$ Million)
10.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2020 - 2033 (US$ Million)
10.6.15.5. Rest of MEA Market Size and Forecast, By Disease, 2020 - 2033 (US$ Million)
11. Key Vendor Analysis- Peptide Drug Conjugates Industry
11.1. Competitive Benchmarking
11.1.1. Competitive Dashboard
11.1.2. Competitive Positioning
11.2. Company Profiles
11.2.1. Novartis AG
11.2.2. AstraZeneca PLC
11.2.3. Oncopeptides AB
11.2.4. Bicycle Therapeutics plc
11.2.5. Cybrexa Therapeutics, Inc.
11.2.6. Angiochem Inc.
11.2.7. Soricimed Biopharma Inc.
11.2.8. Theratechnologies Inc.
11.2.9. PeptiDream Inc.
11.2.10. Curium US LLC
11.2.11. ProteinQure Inc.
11.2.12. Protagonist Therapeutics, Inc.
11.2.13. PepGen Corporation
11.2.14. Italfarmaco S.p.A.
11.2.15. Zealand Pharma A/S
11.2.16. BioNTech SE
11.2.17. Others
12. 360 Degree AnalystView
13. Appendix
13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL PEPTIDE DRUG CONJUGATES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Novartis AG
- AstraZeneca PLC
- Oncopeptides AB
- Bicycle Therapeutics plc
- Cybrexa Therapeutics, Inc.
- Angiochem Inc.
- Soricimed Biopharma Inc.
- Theratechnologies Inc.
- PeptiDream Inc.
- Curium US LLC
- ProteinQure Inc.
- Protagonist Therapeutics, Inc.
- PepGen Corporation
- Italfarmaco S.p.A.
- Zealand Pharma A/S
- BioNTech SE
- Others
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY PRODUCT- MARKET ANALYSIS, 2020 - 2033
- OctreoScan
- Lutathera
- Pluvicto
- Illuccix
- Others
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY TYPE- MARKET ANALYSIS, 2020 - 2033
- Therapeutic
- Diagnostic
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY DISEASE- MARKET ANALYSIS, 2020 - 2033
- Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
- Multiple Myeloma
- Others
GLOBAL PEPTIDE DRUG CONJUGATES MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Denmark
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Taiwan
- Vietnam
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Iran
- Qatar
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Analystview Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
